Film Array by BioFire Defense
The FDA-cleared FilmArray system from BioFire Diagnostics has set a new standard in molecular diagnostics. FilmArray's Respiratory and Blood Culture Identifications panels test for more than a hundred pathogens.
Next Generation Diagnostic System (NGDS) Technology Development contract BioFire received in early 2014 is an 8 year $240M biodefense program. The NGDS program will develop and deliver the new standard of biowarfare detection to the US Department of Defense, replacing the current Joint Biologic Agent Identification and Diagnostic System (JBAIDS).
The FilmArray is also what the medical team at Emory used (RUO) to diagnose the first two Ebola U.S. patients, Kent Brantly and Nancy Writebol. In a recent paper, published in the journal Lab Medicine. They write "Polymerase chain reaction (PCR)–based microbiological analyzer (BioFire FilmArray [BioFire Diagnostics, Inc, Salt Lake City, UT]) designed to detect a panel of viral, bacterial, fungal, or parasitic pathogens, many of which might be found in patients returning from a resource-poor region and might complicate care. Among other pathogen-specific markers, this instrument detects Ebola viralRNA, a capability that we believe could have value for monitoring progression of and recovery from Ebola infection in this setting."
Company is now BioFire Defense and BioFire Diagnostics, and was recently acquired by a French company, bioMérieux, in Jan. 2014.